Literature DB >> 16997458

Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia.

Chandrashekhar D Kamat1, Dixy E Green, Linda Warnke, Jessica E Thorpe, Antonio Ceriello, Michael A Ihnat.   

Abstract

There is much controversy in the literature regarding the role of p53 status response on hypoxia inducible factor (HIF) signaling in response to chronic relative hypoxia (CRH). The goal of this paper was to methodically examine this response in isogenically matched tumor cells. We report that p53-mutant (MUT) cells, versus p53-wild-type (WT) cells, showed decreased apoptosis, increased cell proliferation with higher basal HIF-1alpha levels in response to CRH. In addition, we found increased HIF-mediated transactivation and increased VEGF release with decreased HIF-1alpha/p53 and HIF-1alpha/MDM-2 partnering in p53-MUT versus p53-WT cells in response to CRH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16997458     DOI: 10.1016/j.canlet.2006.08.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  26 in total

1.  A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer.

Authors:  Anja Bastian; Jessica E Thorpe; Bryan C Disch; Lora C Bailey-Downs; Aleem Gangjee; Ravi K V Devambatla; Jim Henthorn; Kenneth M Humphries; Shraddha S Vadvalkar; Michael A Ihnat
Journal:  J Pharmacol Exp Ther       Date:  2015-02-26       Impact factor: 4.030

2.  SOCS3 modulates interleukin-6R signaling preference in dermal fibroblasts.

Authors:  Lerin R Luckett-Chastain; Michael A Ihnat; Bethany M Mickle-Kawar; Randle Michael Gallucci
Journal:  J Interferon Cytokine Res       Date:  2012-02-07       Impact factor: 2.607

3.  Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.

Authors:  Ge Zhou; Jiping Wang; Mei Zhao; Tong-Xin Xie; Noriaki Tanaka; Daisuke Sano; Ameeta A Patel; Alexandra M Ward; Vlad C Sandulache; Samar A Jasser; Heath D Skinner; Alison Lea Fitzgerald; Abdullah A Osman; Yongkun Wei; Xuefeng Xia; Zhou Songyang; Gordon B Mills; Mien-Chie Hung; Carlos Caulin; Jiyong Liang; Jeffrey N Myers
Journal:  Mol Cell       Date:  2014-05-22       Impact factor: 17.970

Review 4.  Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.

Authors:  Mark W Dewhirst; Yiting Cao; Benjamin Moeller
Journal:  Nat Rev Cancer       Date:  2008-06       Impact factor: 60.716

5.  Intermittent hypoxia induces a metastatic phenotype in breast cancer.

Authors:  Anna Chen; Jaclyn Sceneay; Nathan Gödde; Tanja Kinwel; Sunyoung Ham; Erik W Thompson; Patrick O Humbert; Andreas Möller
Journal:  Oncogene       Date:  2018-05-01       Impact factor: 9.867

Review 6.  Reciprocal influence of the p53 and the hypoxic pathways.

Authors:  A Sermeus; C Michiels
Journal:  Cell Death Dis       Date:  2011-05-26       Impact factor: 8.469

7.  A combined gene signature of hypoxia and notch pathway in human glioblastoma and its prognostic relevance.

Authors:  Khushboo Irshad; Saroj Kant Mohapatra; Chitrangda Srivastava; Harshit Garg; Seema Mishra; Bhawana Dikshit; Chitra Sarkar; Deepak Gupta; Poodipedi Sarat Chandra; Parthaprasad Chattopadhyay; Subrata Sinha; Kunzang Chosdol
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240

8.  Identification of novel drugs to target dormant micrometastases.

Authors:  Robert E Hurst; Paul J Hauser; Youngjae You; Lora C Bailey-Downs; Anja Bastian; Stephen M Matthews; Jessica Thorpe; Christine Earle; Lilly Y W Bourguignon; Michael A Ihnat
Journal:  BMC Cancer       Date:  2015-05-14       Impact factor: 4.430

9.  Role of compartmentalization on HiF-1α degradation dynamics during changing oxygen conditions: a computational approach.

Authors:  Baptiste Bedessem; Angélique Stéphanou
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

10.  P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.

Authors:  Rabin Said; David S Hong; Carla L Warneke; J Jack Lee; Jennifer J Wheler; Filip Janku; Aung Naing; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Oncotarget       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.